Naurex

Naurex is a biopharmaceutical company developing novel NMDA receptor modulators for the treatment of challenging diseases of the brain and central nervous system. The lead candidate product, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder who have not had adequate responses to current antidepressants. In Phase II clinical studies, rapastinel has demonstrated rapid, robust, and sustained antidepressant activity with good tolerability and without any psychotomimetic side effects that have limited other drugs targeting the NMDA receptor. Our second-generation compound, NRX-1074, is an orally active agent in Phase II clinical development as a monotherapy for depression.